2025 ICD-10-CM code E85.81
(Active) Effective Date: N/A Systemic amyloidosis - Metabolic disorders (E70-E88) Endocrine, Nutritional and Metabolic Diseases (E00-E89) Feed
Light chain (AL) amyloidosis is a condition characterized by the buildup of abnormal protein fibers, called light chains, in various organs and tissues.
Medical necessity for services related to E85.81 is established by the presence of signs, symptoms, and organ dysfunction related to AL amyloidosis. This may include impaired kidney function, heart failure, peripheral neuropathy, or other organ-specific manifestations.
Clinicians diagnosing and managing AL amyloidosis typically include nephrologists, cardiologists, hematologists, and oncologists, depending on the affected organ systems. Their responsibilities include evaluating organ damage,suppressing the production of abnormal light chains, and providing supportive care to manage symptoms.
In simple words: AL amyloidosis is a disease where your body makes abnormal proteins that clump together and harm your organs, especially your kidneys and heart.
Light chain (AL) amyloidosis is a systemic disorder caused by abnormal functioning of the immune system.It leads to the overproduction of immunoglobulin light chains, which misfold and aggregate into amyloid fibrils.These fibrils deposit in tissues and organs, disrupting normal function and causing a range of symptoms.The kidneys and heart are most commonly affected, but other organs can be involved as well.
Example 1: A patient presents with fatigue, swelling in the ankles, and shortness of breath.Tests reveal impaired kidney function and proteinuria.A kidney biopsy confirms the presence of amyloid deposits composed of light chains, leading to a diagnosis of AL amyloidosis., A patient with a history of multiple myeloma develops heart failure symptoms.An echocardiogram shows thickened heart walls with restrictive cardiomyopathy. Further investigation, including a heart biopsy, confirms amyloid deposition related to light chain production, establishing a diagnosis of AL amyloidosis., A patient experiences numbness and tingling in their hands and feet (peripheral neuropathy).During evaluation for peripheral neuropathy, blood tests reveal the presence of monoclonal light chains. Tissue biopsy confirms amyloid deposits and diagnoses AL amyloidosis affecting the peripheral nervous system.
Documentation for E85.81 should include evidence from biopsy demonstrating amyloid deposits consisting of monoclonal light chains, details of involved organs (kidney, heart, etc.), and any related underlying conditions such as multiple myeloma.
- Specialties:Nephrology, Cardiology, Hematology, Oncology
- Place of Service:Inpatient Hospital, Outpatient Hospital, Office